PATTERSON COMPANIES, INC. (NASDAQ:PDCO) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

(b), (c) and (e)On May23, 2018, Patterson Companies, Inc. (the “Company”) announced that its Board of Directors (“Board”) has appointed Donald J. Zurbay as the Company’s Chief Financial Officer, effective June29, 2018 (the “Effective Date”), and that Dennis W. Goedken, who has been serving as the Company’s Interim Chief Financial Officer since March1, 2018, will step down from such position at that time. Mr.Goedken will continue to serve as the Company’s Controller.

Mr.Zurbay, age 50, most recently served as Vice President and Chief Financial Officer at global medical device manufacturer St. Jude Medical, Inc. from August 2012 through the January 2017 acquisition of St. Jude Medical by Abbott Laboratories. At St. Jude Medical, Mr.Zurbay was responsible for all accounting, financial and business development activities. He joined St. Jude Medical in 2003 and held various leadership positions, including Director of Finance and Vice President and Corporate Controller. Prior to joining St. Jude Medical, Mr.Zurbay worked at PricewaterhouseCoopers for five years as an Assurance and Business Advisory Services Senior Manager. Before joining PricewaterhouseCoopers, he was a General Accounting Manager at The Valspar Corporation. Mr.Zurbay started his career at Deloitte& Touche as an auditor in 1989. There are no familial relationships between Mr.Zurbay and any other director or executive officer of the Company. There are no transactions in which Mr.Zurbay has an interest requiring disclosure under Item 404(a) of Regulation S-K.

In connection with his employment, Mr.Zurbay and the Company entered into an Offer Letter effective May17, 2018 (the “Offer Letter”), which is filed as Exhibit 10.1 to this Current Report on Form 8-K and is incorporated by reference herein. Mr.Zurbay and the Company are expected to enter into an Inducement, Severance& Change in Control Agreement (the “Agreement”), the form of which is filed as Exhibit 10.2 to this Current Report on Form 8-K and is incorporated by reference herein.

to the Offer Letter, Mr.Zurbay’s employment will be on an at-will basis. The Offer Letter provides for an annual base salary of $525,000 as well as participation in the Company’s other employee benefit plans and reimbursement for business expenses. Mr.Zurbay also will be eligible to earn annual cash incentive compensation, which is payable if a threshold level of performance is achieved, to the Company’s Management Incentive Compensation Plan (“MICP”). If performance at target under the MICP is achieved, Mr.Zurbay’s annual cash incentive compensation would be 85% of his base salary. In addition, Mr.Zurbay will be eligible to receive annual long-term equity-based incentive compensation to the Company’s 2015 Omnibus Incentive Plan (“Omnibus Plan”), or any successor plan thereto, which awards currently consist of restricted stock units, performance stock units, and stock options, with an aggregate target value of $1,000,000. The equity awards for fiscal year 2019 will be granted on July1, 2018. Mr.Zurbay’s base salary, annual cash incentive compensation, and annual long-term equity-based incentive compensation will be reviewed on an annual basis and may be adjusted by the Board.

The Agreement provides for an inducement award consisting of a combination of stock options and restricted stock units. Subject to execution of the Agreement, Mr.Zurbay will be granted a non-statutory stock option and a restricted stock unit award, both outside the Omnibus Plan, on the Effective Date. The stock option will have an approximate value of $750,000, a per-share exercise price equal to the per-share closing price of the Company’s common stock on the date of grant, and a term of ten years. Such award will vest, subject to continued employment, to the extent of one-third of the award on the first anniversary of the date of grant, one-third of the award on the second anniversary of the date of grant, and the remaining one-third of the award on the third anniversary of the date of grant. The restricted stock unit award will cover a number of shares of the Company’s common stock with a value of $700,000 based on the per-share closing price of the Company’s common stock on the date of grant. Such award will vest,

1

assuming continued employment, to the extent of 50% of the award on the first anniversary of the date of grant and the remaining 50% of the award on the second anniversary of the date of grant. The other terms and conditions of the inducement award are set forth in the Inducement Non Statutory Stock Option Agreement and the Inducement RSU Agreement, the forms of which are filed as Exhibits 10.3 and 10.4 to this Current Report on Form 8-K and are incorporated by reference herein.

Under the Agreement, if the Company terminates Mr.Zurbay without cause, Mr.Zurbay would be entitled to severance benefits including (a)one-and-one-half (1.5) times his then current base salary, (b)cash incentive compensation equal to an average of the last three years of actual MICP incentives, (c)proration of the current year MICP incentive based on actual performance, and (d) 18 months of COBRA. With a change in control and a termination without cause or a resignation for good reason, such severance benefits would include (a)two (2) times his then current base salary, (b)cash incentive compensation equal to his then current target MICP incentive, (c)proration of the current year MICP incentive based on target performance, and (d) 18 months of COBRA.

As set forth in the Agreement, Mr.Zurbay also will agree to certain nondisclosure and non-disparagement provisions during his employment and any time thereafter, and certain non-competition and non-solicitation provisions during his employment and for 24 months thereafter.

A copy of the press release issued by the Company on May23, 2018 announcing, among other things, the leadership change described herein is furnished as Exhibit 99 to this Current Report on Form 8-K and is incorporated by reference herein. The information in Exhibit 99 shall not be deemed “filed” for purposes of Section18 of the Exchange Act and shall not be deemed incorporated by reference into any filing under the Securities Act.

(d)Exhibits

2

PATTERSON COMPANIES, INC. Exhibit
EX-10.1 2 d591611dex101.htm EX-10.1 EX-10.1 Exhibit 10.1 PATTERSON COMPANIES | 1031 Mendota Heights Road | Saint Paul,…
To view the full exhibit click here

About PATTERSON COMPANIES, INC. (NASDAQ:PDCO)

Patterson Companies, Inc. is a distributor serving the dental, veterinary and rehabilitation supply markets. The Company operates through three segments: dental supply, veterinary supply and rehabilitation supply. The dental supply segment provides a range of consumable dental products, clinical and laboratory equipment, and value-added services to dentists, dental laboratories, institutions and other dental healthcare providers across North America. The veterinary supply segment is a distributor of veterinary supplies, primarily to companion-pet (dogs, cats and other common household pets) and equine veterinary clinics. The rehabilitation supply segment provides a range of distributed and self-manufactured rehabilitation medical supplies and assistive products to acute care hospitals, long-term care facilities, rehabilitation clinics, dealers and schools. The Company’s operating units include Patterson Dental, Patterson Veterinary and Patterson Medical.